Meet the Fundación MEDINA team at #BioSpain2026! Our representatives will be in #Bilbao from September 29 to October 1 to showcase MEDINA’s expertise and connect with the biotech community.

ROBOCOOP-EU is heading to Istanbul! 15–17 Sept 2026 Our first in-person workshop since the project relaunch will bring partners together around: 🔬 Technology & scale-up ♻️ Circular value chains 🤝 Cooperative business models 🌱 Living Labs 📈 Exploitation & impact 🌍 Community of Practice

The RAFIKI Comprehensive Drug Discovery and Development Workshop is taking place in Nairobi, Kenya, from September 8–11, 2026.

Let’s meet at BIOSPAIN Bilbao! 🧬 We’re looking forward to connecting with biotech and pharma teams, researchers and innovators working on the next generation of drug discovery.

Así ha sido el primer semestre de 2026 para Fundacion MEDINA: más proyectos, más publicaciones internacionales y un crecimiento económico que refuerza nuestra capacidad de seguir investigando desde #Granada www.granadadigital.es/fundacion-me... Fundación PTS Granada #SomosGranadaSalud #Investigación

En ciencias de la vida, pasar de una idea a un producto es un camino largo y complejo. Fundacion MEDINA puede ser el empuje que muchas empresas necesitan. Olga Genilloud, Directora Científica de MEDINA, nos explica cómo la Fundación actúa como plataforma y catalizador para empresas emergentes

La #ciencia de alto nivel no solo genera conocimiento. También genera empleo de calidad. Fundacion MEDINA es un ejemplo de ello. Diego Pozas, Gerente, nos habla de la apuesta de MEDINA por atraer y retener talento científico en #Granada. 👇 Descúbrelo en el video #Investigación #FundacionMEDINA

#Granada avanza como referente científico y biotecnológico a nivel nacional. Y @medinadiscovery.bsky.social tiene mucho que aportar en ese camino Olga Genilloud, Directora Científica de MEDINA, nos lo explica Puedes ver la entrevista completa en Granada Digital www.granadadigital.es/granada-cien...

Fundación MEDINA nació en #Granada con una misión clara: convertirse en un referente independiente de I+D e innovación en salud. Pero, ¿por qué Granada? 👇Diego Pozas, Gerente de MEDINA, nos cuenta el origen de la Fundación y el papel que juega hoy en el ecosistema científico y empresarial andaluz.

It was a pleasure to attend ACI Biopesticides Europe 2026 and connect with colleagues, researchers, and industry experts from across the sector. During his presentation, Víctor González-Menéndez, shares MEDINA's insights and contributes to the discussion on innovation in biopesticides.

Our team is delighted to celebrate Fundación MEDINA’s recognition as an Official Partner Site for screening within the European Research Infrastructure @eu-openscreen.bsky.social

🎉 What a time in #Vienna! @medinadiscovery.bsky.social was proud to be part of SLAS 2026, one of Europe's leading conferences bringing together the drug discovery and laboratory innovation community. #SLASEurope2026 #DrugDiscovery #Oncology #MachineLearning #NaturalProducts #FundaciónMEDINA

🔔 Reminder! The next EUREMAP Seminar Series session co-organised by Fundación MEDINA is happening next Wednesday, May 27! If you haven't registered yet, there is still time: zoom.us/meeting/regi... Don't miss out on the opportunity to hear from Dr. Paul Jensen research on Natural Product Discovery

Welcome! You are invited to join a meeting: MEDINA Seminar Series - Dr. Paul Jensen. After registering, you will receive a confirmation email about joining the meeting.

Welcome! You are invited to join a meeting: MEDINA Seminar Series - Dr. Paul Jensen. After registering, you will receive a confirmation email about joining the meeting.

zoom.us

Fundación MEDINA@medinadiscovery.bsky.social · 5mo ago

📢Save the Date📢 Join us for the next session of the online @euremap.bsky.social Seminar Series, hosted by @medinadiscovery.bsky.social The seminar will feature Dr. Paul Jensen (Scripps Institution of Oceanography, UC San Diego) who will discuss on “Changing paradigms in Natural product discovery"

Excited to share our latest publication in the Journal of Natural Products! This research was carried out within the framework of the HOTBIO project, in collaboration with University of Galway. 🔗 Read the article here: pubs.acs.org/doi/10.1021/...

Sulphopreussomerins: Sulfur-Containing Preussomerins Isolated from the Marine-Derived Fungus Pyrenochaetopsis indica

The organic extract of Pyrenochaetopsis indica CF-301929, a fungal strain collected from the Coral Sea in Australia, showed broad-spectrum activity against the fungal phytopathogens Zymoseptoria tritici, Colletotrichum acutatum, Fusarium proliferatum, and Magnaporthe grisea. After extensive purification, five compounds were isolated, including three new sulfur containing preussomerins 1–3 along with two previously described molecules, ascochytatin (4) and preussomerin G (5). The new compounds incorporate rare thioglycolic or 2-hydroxy-3-mercaptopropionic acid moieties in their structures, and they represent the first members of a new class of preussomerins that we have named sulphopreussomerins. Multiple spectroscopic analyses, including HRESIMS and 1D/2D NMR experiments were used to elucidate their structures while the proposed absolute configuration of compound 1 was assigned by comparison of the experimental and theoretical ECD spectra. When tested against a fungal phytopathogen panel, preussomerin G exhibited, as previously reported, strong antifungal activity and cytotoxicity, whereas sulphopreussomerin A and ascochytatin showed moderate antifungal activity against Z. tritici with no detectable cytotoxicity.

pubs.acs.org

En @medinadiscovery.bsky.social hemos tenido el placer de recibir a los estudiantes de la asignatura Química de Productos Naturales del Grado en Química de la @universidadjaen.bsky.social , en una visita junto al profesor Antonio Marchal #UJAen #FundacionMEDINA #QuimicaDeProductosNaturales

🚀 @medinadiscovery.bsky.social is heading to #SLAS2026 in #Vienna! Our Head of Screening and Target Validation, Rosario Fernández Godino, will be presenting m3DinAI, our newest imaging platform for the screening of antitumoral drugs. 📍 Thursday, May 21, 2026 · 11:30 CEST

📢Save the Date📢 Join us for the next session of the online @euremap.bsky.social Seminar Series, hosted by @medinadiscovery.bsky.social The seminar will feature Dr. Paul Jensen (Scripps Institution of Oceanography, UC San Diego) who will discuss on “Changing paradigms in Natural product discovery"

Rosario Fernández-Godino, Head of Screening at @medinadiscovery.bsky.social , presented the latest results of the #NATMAC project at the ARVO Annual Meeting 2026 (Denver, Colorado).

Does your compound deserve a better cell-based assay? At @medinadiscovery.bsky.social we design, optimise and run cell-based assays tailored to your specific biological question: from validated platforms to fully custom solutions and end-to-end screening workflows.

Validating antigen-antibody interactions is a cornerstone of R&D, yet traditional methods like ELISA can often become bottlenecks due to their cost, time requirements, and lack of scalability.

@medinadiscovery.bsky.social is part of the #NOVA-VRE project, aimed at developing new therapies against infections caused by vancomycin-resistant Enterococcus faecium. Read the full piece here: www.medinadiscovery.com/medina-parti... Stay tuned for updates! 🔬

MEDINA participates in the NOVA-VRE project to develop new therapies to combat antibiotic-resistant bacteria. - Fundación MEDINA

MEDINA participates in the NOVA-VRE project to develop new therapies to combat antibiotic-resistant bacteria. Granada, April 13, 2026 Fundación MEDINA is part of the NOVA-VRE consortium, an R&D projec...

medinadiscovery.com

Hit prioritization through orthogonal binding assays. In drug discovery, identifying hits is only the beginning; the real challenge lies in prioritizing them correctly to eliminate false positives and ensure only the most promising candidates move forward.

From a conventional enzymatic assay to a high-throughput screening platform in weeks. Transitioning an optimized in vitro assay from an academic setting to high-throughput screening requires more than just automation; it demands a fundamental redesign of the assay’s robustness.

The evaluation of metabolic stability is a standard procedure in early drug discovery. However, relying solely on disappearance rates often overlooks the formation of active or reactive metabolites. These unidentified species can cause toxicity, leading to late-stage dropout.

Entering regulatory phases with the wrong candidate is a costly mistake. The key to efficiency in Drug Discovery lies in the preliminary phase: Non-GLP Preclinical Research. At @medinadiscovery.bsky.social , we offer a flexible and cost-effective approach to Non-GLP Preclinical Studies.

Ayer en @medinadiscovery.bsky.social recibimos la visita de los alumnos del Máster en Biología Agraria y Acuicultura de la Universidad de Granada, acompañados por el profesor Alberto Bago, Estación Experimental del Zaidín-CSIC.

Tomorrow is Rare Disease Day While individual rare diseases affect a small number of people, their collective impact is a global health challenge. #RareDiseaseDay #GeneEditing #iPSC #Biotech

🚀 New Article Published! Unlocking the Power of Non GLP Preclinical Studies in Drug Discovery! www.medinadiscovery.com/wp-content/u... 👉 Elevate your pipeline. Reduce risk. Accelerate innovation #ADME-tox #DrugDevelopment #BienestarAnimal #SECAL #COSCE #FundacionMEDINA #AnimalResearch

Last week, our doctoral student Gioele Pecin presented a poster at the Natural Products in the 21st Century conference in #Leuven. He explained how he managed to heterologously express the main genes of the biosynthetic cluster of a new fungal natural product in a black yeast host.

Excited to participate in the IQF Technical-Scientific Symposium in Madrid, March 10th. Join us to explore new trends in molecular interactions. Full agenda and registration: nanotempertech.com/events/works...